Current status of immunotherapy in gastric cancer

Abstract

Gastric cancer is one of the most common cancer with high mortality and morbilidity in East Asia, especially in China. In recent year, new treatment strategies for gastric cancer have developed. Immune check point inhibitors (ICIs) have been detected as a new standard treatment in Gastric cancer, which helped to improve the prognosis of patients with gastric cancer. Attempts to combine immunotherapy have become one of the research focuses. In this article, application of immunotherapy in neoadjuvant therapy and translational treatment of gastric cnacer are reviewed. Which is expected to be a reference for comprehensive treatment plan of accurate treatment methods for gastric cancer patients. In order to provide experiences and reference to develop individualized treatment of gastric cancer in clinical practice.